Evidence map›Paper›PMID 34271164›Full record

ArticlePulmonary pharmacology & therapeutics2021

Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians.

Hong-Long Ji, Brant M Wagener, Timothy J Ness, Runzhen Zhao

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary pharmacology & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hong-Long JiDepartment of Cellular and Molecular Biology, University of Texas Health Science Centre at Tyler, Tyler, TX 75708, USA; Texas Lung Injury Institute, The University of Texas Health Science Centre at Tyler, Tyler, TX 75708, USA. Electronic address: james.ji@uthct.edu.
Brant M WagenerDivision of Molecular and Translational Biomedicine, USA; Division of Critical Care Medicine, Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: bwagener@uabmc.edu.
Timothy J NessDivision of Molecular and Translational Biomedicine, USA. Electronic address: tness@uabmc.edu.
Runzhen ZhaoDepartment of Cellular and Molecular Biology, University of Texas Health Science Centre at Tyler, Tyler, TX 75708, USA. Electronic address: Zhao@uthct.edu.

Funding

QUANTITATIVE STUDY OF URINARY BLADDER SENSORY PROCESSINGR01DK051413 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DEBERRY, JENNIFER J, NESS, TIMOTHY J · 1997 to 2025
$5.4M
NOVEL PARACRINE MECHANISMS FOR CELL-BASED THERAPY OF INJURED LUNGSR01HL134828 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI JI, HONG-LONG · 2017 to 2025
$3.4M
The Role of Sex Dimorphism in Post-TBI Bacterial PneumoniaR01GM127584 · NIGMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WAGENER, BRANT M · 2018 to 2022
$1.9M
Regulation of lung epithelial sodium channels by cGMPR01HL087017 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI JI, HONG-LONG · 2007 to 2011
$1.6M
NHLBI NIH HHS R01 HL087017NHLBI NIH HHS R01 HL134828NIDDK NIH HHS R01 DK051413NIGMS NIH HHS R01 GM127584
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentFibrinolysinBenzamidinesGuanidinesHumansBenzamidinesFibrinolysinGuanidinesnafamostatAnti-ProteaseCOVID-19Fibrinolytic therapyPlasmin

Identifiers

PMID34271164
PMCPMC8276553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.